Oppenheimer Cites “Abundance of Support” for Capricor’s Deramiocel Ahead of November FDA Decision
Oppenheimer says Capricor’s Q3 update shows strong support for deramiocel in Duchenne. FDA decision expected around Nov 22; stock could hit $50.
/ 15 items
#CAPR↓
Capricor’s HOPE-3 Extension Shows 76% Slower Arm Decline in DMD, but Analysts Still Expect an FDA Rejection
New Capricor extension data support slower DMD arm decline, but H.C. Wainwright and Roth still see a complete response letter as more likely.
B. Riley Turns Bullish on Capricor Before November Deramiocel Decision
B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.
Piper Sandler Upgrades Capricor to Overweight, Lifts Target to $25 After FDA Review Extension
Capricor stock jumped after Piper Sandler turned bullish, citing a better risk-reward into the Nov. 22 FDA ruling on its DMD therapy.
Wall Street Turns Bullish on Capricor as FDA Extends Review for Deramiocel to November
Oppenheimer raises Capricor to Outperform on clearer path for deramiocel. $54 target, PDUFA Nov 22 after upper-limb focus.
Capricor Gets Three Extra Months as FDA Reviews Stronger Upper-Limb Data for Deramiocel
FDA extends Capricor’s Deramiocel BLA review to Nov 22, 2026 after new 24-month HOPE-3 data focused on upper limb function in Duchenne MD.